GI INNOVATION, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,180 KRW | -1.32% |
|
-3.70% | -7.22% |
| 2023 | GI Innovation, Inc.(KOSDAQ:A358570) added to S&P Global BMI Index | CI |
| 2023 | GI Innovation, Inc. has completed an IPO in the amount of KRW 26 billion. | CI |
| 1 day | -1.32% | ||
| 1 week | -3.70% | ||
| Current month | -3.70% | ||
| 1 month | -15.62% | ||
| 3 months | -18.99% | ||
| 6 months | +14.08% | ||
| Current year | -7.22% |
1 week
10 880.00
12 210.00
1 month
10 880.0014 000.00
Current year
9 810.0014 650.00
1 year
8 080.0015 700.00
3 years
8 080.0015 700.00
5 years
8 080.0015 700.00
10 years
8 080.0015 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jun-Ho Hong
CEO | Chief Executive Officer | 52 | - |
Byeong-Geon Lee
CEO | Chief Executive Officer | 67 | 22-03-03 |
Jin-Man Kim
DFI | Director of Finance/CFO | 42 | 17-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byeong-Geon Lee
CEO | Chief Executive Officer | 67 | 22-03-03 |
Su-Yeon Nam
PSD | President | 58 | 18-11-30 |
Geun-Yong An
BRD | Director/Board Member | 49 | 22-02-28 |
GI Innovation Inc is a Korea-based company engaged in the research and development of next-generation immunotherapies based on fusion proteins. The Company is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.22% | 359M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- A358570 Stock
